Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
Public ClinicalTrials.gov record NCT04085367. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis (AK) of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT).
Study identification
- NCT ID
- NCT04085367
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 557 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2019 (Actual)
- Primary completion
- Mar 3, 2021 (Actual)
- Completion
- Apr 7, 2021 (Actual)
- Last update posted
- Apr 1, 2022
2019 – 2021
United States locations
- U.S. sites
- 59
- U.S. states
- 28
- U.S. cities
- 55
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Galderma Investigational Site (Site 8768) | Tucson | Arizona | 85718 | — |
| Galderma Investigational Site (Site 8447) | Fort Smith | Arkansas | 72916-6103 | — |
| Galderma Investigational Site (Site 8577) | Encinitas | California | 92024 | — |
| Galderma Investigational Site (Site 8636) | Fountain Valley | California | 92708 | — |
| Galderma Investigational Site (Site 8224) | Fremont | California | 94538 | — |
| Galderma Investigational Site (Site 8114) | Fresno | California | 93720 | — |
| Galderma Investigational Site (Site 8758) | San Diego | California | 92121 | — |
| Galderma Investigational Site (Site 8608) | Santa Monica | California | 90404 | — |
| Galderma Investigational Site (Site 8778) | Denver | Colorado | 80210 | — |
| Galderma Investigational Site (Site 8440) | Greenwood Village | Colorado | 80111 | — |
| Galderma Investigational Site (Site 8479) | Bradenton | Florida | 34209 | — |
| Galderma Investigational Site (Site 8770) | Lehigh Acres | Florida | 33936 | — |
| Galderma Investigational Site (Site 8656) | Miami | Florida | 33137 | — |
| Galderma Investigational Site (Site 8765) | North Miami Beach | Florida | 33162 | — |
| Galderma Investigation Site (Site 8769) | Palm Springs | Florida | 33461 | — |
| Galderma Investigational Site (Site 8734) | Pembroke Pines | Florida | 33028 | — |
| Galderma Investigational Site (Site 8529) | Sanford | Florida | 32771 | — |
| Galderma Investigational Site (Site 8126) | West Palm Beach | Florida | 33401 | — |
| Galderma Investigational Site (Site 8683) | Atlanta | Georgia | 30342-1418 | — |
| Galderma Investigational Site (Site 8860) | Atlanta | Georgia | 30342 | — |
| Galderma Investigational Site (Site 8667) | Columbus | Georgia | 31904 | — |
| Galderma Investigational Site (Site 8755) | Boise | Idaho | 83704 | — |
| Galderma Investigational Site (Site 8838) | Darien | Illinois | 60561 | — |
| Galderma Investigational Site (Site 8724) | Louisville | Kentucky | 40241 | — |
| Galderma Investigational Site (Site 8208) | Beverly | Massachusetts | 01915 | — |
| Galderma Investigational Site (Site 8574) | Clarkston | Michigan | 48346-3198 | — |
| Galderma Investigation Site (Site 8757) | Saint Joseph | Michigan | 49085 | — |
| Galderma Investigational Site (Site 8762) | Edina | Minnesota | 55424-1200 | — |
| Galderma Investigational Site (Site 8140) | New Brighton | Minnesota | 55112 | — |
| Galderma Investigational Site (Site 8219) | St Louis | Missouri | 63141 | — |
| Galderma Investigational Site (Site 8869) | St Louis | Missouri | 63141 | — |
| Galderma Investigational Site (Site 8048) | Omaha | Nebraska | 68144 | — |
| Galderma Investigational Site (Site 8420) | Portsmouth | New Hampshire | 03801 | — |
| Galderma Investigational Site (Site 8759) | Albuquerque | New Mexico | 87102 | — |
| Galderma Investigational Site (Site 8242) | Brooklyn | New York | 11203 | — |
| Galderma Investigational Site (Site 8733) | New York | New York | 10022 | — |
| Galderma Investigational Site (Site 8279) | New York | New York | 10075 | — |
| Galderma Investigational Site (Site 8566) | Charlotte | North Carolina | 28277 | — |
| Galderma Investigational Site (Site 8726) | Wilmington | North Carolina | 28405-3176 | — |
| Galderma Investigational Site (Site 8595) | Dublin | Ohio | 43016 | — |
| Galderma Investiational Site (Site 8212) | Portland | Oregon | 97210-2996 | — |
| Galderma Investigational Site (Site 8255) | Philadelphia | Pennsylvania | 19103 | — |
| Galderma Investigational Site (Site 8721) | Pittsburgh | Pennsylvania | 15213 | — |
| Galderma Investigational Site (Site 8754) | Sugarloaf | Pennsylvania | 18249 | — |
| Galderma Investigational Site (Site 8777) | Charleston | South Carolina | 29407 | — |
| Galderma Investigational Site (Site 8207) | Nashville | Tennessee | 37215 | — |
| Galderma Investigational Site (Site 8076) | Austin | Texas | 78759 | — |
| Galderma Investigational Site (Site 8139) | College Station | Texas | 77845 | — |
| Galderma Investigational Site (Site 8664) | Frisco | Texas | 75034 | — |
| Galderma Investigational Site (Site # 8576) | Houston | Texas | 77056 | — |
| Galderma Investigational Site (Site 8546) | Pflugerville | Texas | 78660-3519 | — |
| Galderma Investigational Site (Site 8672) | Salt Lake City | Utah | 84117 | — |
| Galderma Investigational Site (Site 8776) | St. George | Utah | 84790 | — |
| Galderma Investigational Site (Site 8761) | West Jordan | Utah | 84101 | — |
| Galderma Investigational Site (Site 8057) | Lynchburg | Virginia | 24501 | — |
| Galderma Investigational Site (Site 8779) | Burien | Washington | 98168 | — |
| Galderma Investigational Site (Site 8039) | Spokane | Washington | 99202 | — |
| Galderma Investigational Site (Site 8760) | Spokane | Washington | 99202 | — |
| Galderma Investigational Site (Site 8725) | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04085367, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2022 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04085367 live on ClinicalTrials.gov.